anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this trial, participants will be assigned randomly to have their surgical skin site prepared for surgery with either chlorhexidine gluconate-alcohol solution or povidone-iodine solution. These are two types of solutions that have antiseptic properties, which means they help eliminate harmful bacteria on the skin at the time of surgery, and therefore, reduce the risk of infection. Surgeons routinely use either chlorhexidine-based or iodine-based skin preparation solutions at the time of surgery to sterilize the surgical area. However, we don't know which one works best for patients having revision joint replacement surgery. There is a small chance of having an allergic reaction to the chlorhexidine or iodine, but there is no additional risk by participating in this study, as these skin preparation solutions are routinely used in practice.

The main outcome of interest is the need for re-operation for a wound complication or an infection of the prosthetic joint within one year after surgery. Other key outcomes are surgical site infection, mortality, and readmission to hospital. Participants will be contacted 30 days after surgery to complete a survey online, by phone, or in person, which will take approximately 5 minutes to complete. All other outcome data will be collected by phone call, health records, routine hospital monitoring, or electronic registry data at thirty days and one year after surgery.

You may choose to participate in this trial, or not. If you decide to participate, you will be randomly assigned (like flipping a coin) by a computer, to one of the possible interventions. You will be told which group you have been assigned to. Participating in this program is your choice (i.e., is voluntary). You have the right to choose not to participate, or to stop participating in this program at any time. Your decision will not affect the care you receive at this time, or in the future. As part of this program, we will use data that is already routinely collected from your hospital stay for administrative and quality-improvement purposes. We will collect your OHIP number to securely link the records we collect to other databases already collected. We will also collect your first and last name, email address and phone number, for follow-up survey purposes. The person conducting this study and other study staff will keep the information they see or receive about you confidential. Your de-identified study information will be kept in a secure and confidential location and then destroyed according to institutional policy. You will not be paid for taking part in this study and there will be no costs associated with participation. If you agree to take part, there may or may not be any direct benefit to you. You will receive a Research Study Information Sheet for your reference. The Research Ethics Board that oversees the ethical conduct of this study may review your relevant study records for audit purposes.
If the patient self-identifies as a smoker, the investigators will consent and randomize to receive the intervention or not. Either way, all will receive a baseline attitude survey. The patient will be given a series of questions that target the areas of interest noted in the model. At some point in their hospitalization, preferably at least one day later and no greater than one week later, the patients will be given the teaching intervention (or not), and receive another attitude survey. After discharge, the patients will be expected in orthopaedic follow up clinic. At that time they will receive another attitude survey. If unable to deliver at that time, they will be contacted by phone or sought at their second clinic follow up.
All the participants receive as active treatment a form of psychotherapy for personality disorders (Evolutionary Systems Therapy). The treatment last 6 months (24 weekly sessions, each lasting 50-60 minutes).
Devices and methods are provided for image identification of contrast agents comprising nanopartiles. The imaging devices and methods may also be configured to identify target tissues from surrounding tissues such as disease conditions (e.g. cancer tumors) through narrow-band imaging of tissue. Contrast agents such as near-infrared absorbing nanoparticles may be introduced to an organism to distinguish target cells, tissues, or structures from normal tissue. The contrast agent is allowed to preferentially accumulate in the target cells, tissues or structures. As the contrast agents are adapted to preferentially absorb one or more wavelengths of light, the reflection of one wavelength or band of wavelengths by the contrast agents is compared to a separate wavelength or band of wavelengths to identify the target cells, tissues, or structures. In this way, the comparisons identify the presence of the preferential accumulation of the contrast agent in the target cells, tissues or structures.
INTRODUCTION: A recent consensus meeting (RE.GA.IN) addressed "host-related, low-prevalence gastritis": eosinophilic (EoG), lymphocytic (Hp-pos_LyG and Hp-neg_LyG), collagenous (CollG), and granulomatous gastritis (GrG). Our study evaluates their clinico-epidemiological characteristics.
MATERIALS AND METHODS: We extracted all patients with a diagnosis of EoG, LyG, CollG, and GrG from a clinicopathological database and compared their demographics, clinical and endoscopic characteristics, associated conditions, and clinical awareness to those of all other subjects in the database (controls).
RESULTS: There were 1,781,005 unique patients (median age 57 years; 55.7 % female). Hispanics were overrepresented amongst those with Hp-pos_LyG. Subjects with GrG had a high prevalence of erosions and ulcers. Clinical awareness of these conditions was dismal (<1:10,000 patients). Some clinical manifestations were more common in patients with certain gastritides (e.g., vomiting and diarrhea in CollG; anemia in LyG), but none were sufficiently distinctive to suggest a clinical diagnosis. EoG was associated with EoE; LyG had a strong association with celiac disease; CollG with microscopic colitis; and GrG with Crohn disease.
CONCLUSIONS: The diagnosis of these gastritides (between <1: in 1,000 and 1 in 5000 subjects) rests on histopathology. They remain poorly characterized and clinically neglected. Yet, their associations may herald other conditions: eosinophilic gastrointestinal diseases (EGID), celiac, and Crohn disease. Patients might benefit from increased detection and characterization.
This is a randomized cross over study. A convenience sample of staff and resident physicians and physician assistants from the San Antonio Military Medical Center (SAMMC) Department of Emergency Medicine will be used to assess NIPPV mask seal during CPAP administration with and without nasal cannula. Volunteers will be solicited via Grand Rounds and staff meetings at San Antonio Military Medical Center. Subjects will undergo permuted block randomization by random number generator to the order of intervention, mask alone or mask with nasal cannula at 15L/min of oxygen. An emergency medicine trained physician will place equipment and operate the ventilator. After placement of the NIPPV mask and prior to each study intervention period, appropriate adjustments to enhance mask seal will be made as would happen in a therapeutic setting and the volunteer will be allowed up to two minutes to acclimate to continuous noninvasive positive pressure ventilation. Mask leak will be measured by the ventilator unit and will be recorded after 60 seconds of spontaneous restful ventilation.
Pregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with standard MMS delivery strategy (MMS orientation only). (1 sub-district within each of the 13 districts with high- or moderate-intensity evaluation).
PURPOSE: To obtain the subject diagnostic capable of causing a clear contrast of the lesion of arteriosclerosis by X-ray irradiation from the outside of the body, containing a complex of an X-ray blocking metal and a porphyrin. CONSTITUTION: This diagnostic for arteriosclerosis contains a complex of an X-ray blocking metal such as gold or platinum and a porphyrin such as coproporphyrin III, coproporphyrin I, uroporphyrin III, uroporphyrin I or protoporphyrin IX. The complex is prepared by the following process: a halide (e.g. chloride) of a metal such as gold or platinum and a porphyrin and dissolved in a solvent followed by conducting a reaction, as necessary, under heating, and the reaction product is purified and then isolated from the solvent by e.g. isoelectric point precipitation method. The diagnostic is obtained by dissolving or suspending the above metal complex in an aqueous medium (e.g. physiological saline solution), and is administered pref. by intravenous injection at 0.01-50mg/kg body weight in each diagnosis.
A stable, compact, low-viscosity personal care compositions that includes 20-40% total surfactant. The total surfactant includes a branched anionic surfactant and a linear sulfated anionic surfactant. The linear and branched surfactants both have an alkyl tail with more than 12 carbon atoms and are present at ratio of linear to branched surfactant of 0.4 to 5. The personal care composition may optionally include an electrolytic viscosity modifier. The compact shampoo has a viscosity of less than 2000 mPa-s. The compact personal care composition is formulated to enable convenient dilution by a user and, when diluted, provide in a desirable cleaning experience.
INTRODUCTION: Corrected QT interval (QTc)is an established biomarker for drug-induced Torsade de Pointe (TdP), but with concerns for a false positive signal. Clinically, JTpc and TpTec have emerged as ECG sub-intervals to differentiate predominant hERG vs. mixed ion channel blocking drugs that prolong QTc.
METHODS: In a multicentric, prospective, controlled study, different proarrhythmic drug effects on QTc, JTpc and TpTec were characterized with cynomolgus monkeys using telemetry in a Lead II configuration for internal and external telemetry.Drugs and vehicle were administered orally (PO) to group size of 4 to 8 animals, in 4 laboratories.
RESULTS: In monkeys, dofetilide (0.03-0.3 mg/kg) was associated with exposure dependent QTc and JTpc increase, but no significant TpTec effect. Similarly, quinidine (2-50 mg/kg) increased QTc and JTpc but did not change TpTec. Mexiletine (1-15 mg/kg) and verapamil (50 mg/kg) did not induce any significant effect on QTc, JTpc or TpTec.
DISCUSSION: Clinically, predominant hERG blockers (dofetilide and quinidine) prolong QTc, JTpc and TpTec and are associated with increased risk for TdP. Results from this study demonstrate that ECG changes after dofetilide and quinidine administration to telemetered monkeys differ from the clinical response, lacking the expected effects on TpTec. Potential explanations for the lack of translation include physio-pharmacology species differences or ECG recording and analysis methodology variations. Mixed ion channel blockers verapamil and mexiletine administered to monkeys showed no significant QTc, JTpc or TpTec prolongation as expected based on the similar clinical response for these agents.
The disclosure belongs to the technical field of 5-lipoxygenase inhibitors, and particularly relates to application of liensinine as a 5-lipoxygenase inhibitor. Relevant studies in the prior art have shown that 5-LOX plays an important role in the inflammatory response of the body. The 5-LOX inhibitor has good effect on treating inflammation, and chemical monomers with good 5-LOX inhibition activity are obtained by screening from traditional Chinese medicines with anti-inflammatory efficacy in the prior art. The lotus plumule alkali and 5-LOX have good affinity through molecular interaction screening. Based on the results of this study, liensinine is expected to be a powerful chemical entity for the treatment of 5-lipoxygenase-related diseases. Can be used for preparing 5-lipoxygenase inhibitor, experimental model tool medicine of 5-lipoxygenase inhibitor or medicine for treating and preventing leukotriene related diseases.
Coffee is a universal beverage that drives a multi-industry market on a global basis. Today, the sustainability of coffee production is threatened by accelerated climate changes. In this work, we propose the implementation of genomic-assisted breeding for climate-smart coffee in Coffea canephora. This species is adapted to higher temperatures and is more resilient to biotic and abiotic stresses. After evaluating two populations, over multiple harvests, and under severe drought weather condition, we dissected the genetic architecture of yield, disease resistance, and quality-related traits. By integrating genome-wide association studies and diallel analyses, our contribution is four-fold: (i) we identified a set of molecular markers with major effects associated with disease resistance and post-harvest traits, while yield and plant architecture presented a polygenic background; (ii) we demonstrated the relevance of nonadditive gene actions and projected hybrid vigor when genotypes from different geographically botanical groups are crossed; (iii) we computed medium-to-large heritability values for most of the traits, representing potential for fast genetic progress; and (iv) we provided a first step toward implementing molecular breeding to accelerate improvements in C. canephora. Altogether, this work is a blueprint for how quantitative genetics and genomics can assist coffee breeding and support the supply chain in the face of the current global changes.
This is a prospective, multi-center, longitudinal study to evaluate the proportion of cardiovascular events in diabetic mellitus patients identified by HEMOTAG evaluations, utilizing cardiac time interval measurements being treated in outpatient clinics. An enriched diabetic patient population, currently undergoing standard medical care for their diabetes management (per the American Diabetes Association) will be invited to participate within this study. All patients will complete their standard of care assessments including, vital signs, creatinine, eGFR, fasting Cholesterol (including HDL and LDL), HbA1c,and NT-pro BNP, at their regularly scheduled diabetic clinic visits. During the enrollment visit, patients will undergo a baseline HEMOTAG evaluation, cardiovascular event assessment as well as baseline questionnaire assessments. Patients will be shipped a HEMOTAG device with electrodes, and HEMOTAG measurements will be conducted at least three days a week for a 30-day period at-home. This will occur after the Baseline Visit, after the 6-month Visit, and following any hospitalizations due to cardiac events during the 12-month study.

All patients will undergo standard of care follow-up visits at their normal 6 month and 12 month visits and will repeat the HEMOTAG evaluation (in clinic), cardiovascular event assessment, NT-pro BNP, as well as questionnaire assessments. Results of standard of care assessments including, vital signs, creatinine, eGFR, fasting Cholesterol (including HDL/LDL),and HbA1c, will be collected if performed during their regularly scheduled diabetic clinic visits. Throughout the course of this study, all study participant's medical records will reviewed and assessed for the occurrence of cardiac events (including hospitalizations, emergency room visits/urgent care visits, other cardiac assessments, and death) for up to 12 months. Results from cardiac testing (examples: Echo, Cardiac Catheterization, Stress Tests, etc) that may occur during the 12-month monitoring period will be collected as part of this study.
Vibrio cholerae, Ogawa serotype, El Tor biotype, are subjected to the mutagenic N-methyl-N'-nitro-n-nitrosoguanidine (NTG). First generation mutants are screened for toxin production, and in particular the absence of "A" or enzymatically active subunit production and production of B (binding) subunit. Putative A -  B +  mutants are again exposed to NTG and screened for the A -  B +  characteristics. The formula of the native toxin molecule is usually A +  B +   5-6 , the formula for the molecule produced by the selected second generation mutant is A -  B +   5-6 . This mutant strain is used for production of a live attenuated vaccine which can be administered orally. The mutant has been found to induce immunity, in an experimental model system, against subsequent challenge with virulent cholera vibrios. Because of the immunologic relationship to other enterotoxins (such as the heat-labile enterotoxin of Escherichia coli), the mutant may also induce immunity to diarrheal diseases other than cholera. In fact, antiserum to the isolated toxin-related protein produced by the mutant has been shown to neutralize E. coli entero-toxin. The mutant may also be used for the production of "choleragenoid", the non-toxic, highly immunogenic B portion of the cholera enterotoxin (choleragen) without the complication of toxicity associated with the complete enterotoxin.
Alterations in cellular signaling, chronic inflammation, and tissue remodeling contribute to hepatocellular carcinoma (HCC) development. The release of damage-associated molecular patterns (DAMPs) upon tissue injury and the ensuing sterile inflammation have also been attributed a role in HCC pathogenesis. Cargoes of extracellular vesicles (EVs) and/or EVs themselves have been listed among circulating DAMPs but only partially investigated in HCC. Mitochondria-derived vesicles (MDVs), a subpopulation of EVs, are another missing link in the comprehension of the molecular mechanisms underlying the onset and progression of HCC biology. EVs have been involved in HCC growth, dissemination, angiogenesis, and immunosurveillance escape. The contribution of MDVs to these processes is presently unclear. Pyroptosis triggers systemic inflammation through caspase-dependent apoptotic cell death and is implicated in tumor immunity. The analysis of this process, together with MDV characterization, may help capture the relationship among HCC development, mitochondrial quality control, and inflammation. The combination of immune checkpoint inhibitors (i.e., atezolizumab and bevacizumab) has been approved as a synergistic first-line systemic treatment for unresectable or advanced HCC. The lack of biomarkers that may allow prediction of treatment response and, therefore, patient selection, is a major unmet need. Herein, we overview the molecular mechanisms linking mitochondrial dysfunction, inflammation, and pyroptosis, and discuss how immunotherapy targets, at least partly, these routes.
More than 10% of adults in the United States have type 2 diabetes mellitus (DM) with a 2-4 times higher prevalence of ischemic heart disease than the non-diabetics. Despite extensive research approaches to limit this life-threatening condition have proven unsuccessful, highlighting the need for understanding underlying molecular mechanisms. Long noncoding RNAs (lncRNAs), which regulate gene expression by acting as signals, decoys, guides, or scaffolds have been implicated in diverse cardiovascular conditions. However, their role in ischemic heart disease in DM remains poorly understood. We provide new insights into the lncRNA expression profile after ischemic heart disease in DM mice. We performed unbiased RNA sequencing of well-characterized type 2 DM model db/db mice or its control db/+ subjected to sham or MI surgery. Computational analysis of the RNA sequencing of these LV tissues identified several differentially expressed lncRNAs between (db/db sham vs. db/db MI) including Gm19522 and Gm8075. lncRNA Gm-19522 may regulate DNA replication via DNA protein kinases, while lncRNA Gm-8075 is associated with cancer gene dysregulation and PI3K/Akt pathways. Thus, the downregulation of lncRNAs Gm19522 and Gm8075 post-MI may serve as potential biomarkers or novel therapeutic targets to improve cardiac repair/recovery in diabetic ischemic heart disease.
BACKGROUND AND OBJECTIVES: Patient monitoring systems provide critical information but often produce loud, frequent alarms that worsen patient agitation and stress. This may increase the use of physical and chemical restraints with implications for patient morbidity and autonomy. This study analyzes how augmenting alarm thresholds affects the proportion of alarm-free time and the frequency of medications administered to treat acute agitation.
METHODS: Our emergency department's patient monitoring system was modified on June 28, 2022 to increase the tachycardia alarm threshold from 130 to 150 and to remove alarm sounds for several arrhythmias, including bigeminy and premature ventricular beats. A pre-post study was performed lasting 55 days before and 55 days after this intervention. The primary outcome was change in number of daily patient alarms. The secondary outcomes were alarm-free time per day and median number of antipsychotic and benzodiazepine medications administered per day. The safety outcome was the median number of patients transferred daily to the resuscitation area. We used quantile regression to compare outcomes between the pre- and post-intervention period and linear regression to correlate alarm-free time with the number of sedating medications administered.
RESULTS: Between the pre- and post-intervention period, the median number of alarms per day decreased from 1332 to 845 (-37%). This was primarily driven by reduced low-priority arrhythmia alarms from 262 to 21 (-92%), while the median daily census was unchanged (33 vs 32). Median hours per day free from alarms increased from 1.0 to 2.4 (difference 1.4, 95% CI 0.8-2.1). The median number of sedating medications administered per day decreased from 14 to 10 (difference - 4, 95% CI -1 to -7) while the number of escalations in level of care to our resuscitation care area did not change significantly. Multivariable linear regression showed a 60-min increase of alarm-free time per day was associated with 0.8 (95% CI 0.1-1.4) fewer administrations of sedating medication while an additional patient on the behavioral health census was associated with 0.5 (95% CI 0.0-1.1) more administrations of sedating medication.
CONCLUSION: A reasonable change in alarm parameter settings may increase the time patients and healthcare workers spend in the emergency department without alarm noise, which in this study was associated with fewer doses of sedating medications administered.
SIGNIFOR LAR is an injectable cyclohexapeptide, somatostatin analog. Pasireotide exerts its pharmacological activity via binding to somatostatin receptors (SSTR). There are 5 known human somatostatin receptor subtypes: SSTR 1, 2, 3, 4, and 5. These receptor subtypes are expressed in different tissues under normal physiological conditions. Somatostatin analogs bind to SSTRs with different potencies. Pasireotide binds with high affinity to 4 of the 5 SSTRs (see Table 4).
PURPOSE: A composition for coloring keratin fiber containing cationic 3-amino pyrazolo-[1,5-a]-pyridine derivative is provided to strongly light and wash fiber. CONSTITUTION: A composition for coloring keratin fiber contains 3-amino pyrazolo-[1,5-a]-pyridine derivative of chemical formula (I), its salt and solvate in a coloring medium. The content of basic oxide of chemical formula (I) is 0.001~10 weight% based on total weight. The composition additionally contains metha-phenyleneamine, metha-aminophenol, metha-diphenol, naphthalene coupler, heterocyclic coupler or their additive salt or their mixture. The content of couplers is 0.001~10 weight% based on total weight of the composition. The composition is applied in coloring under the presence of oxidizing agent. The oxidizing agent is hydrogen peroxide, carbamide peroxide, alkali metal bromated, per-salt, peracid or oxidase.